Status:
COMPLETED
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Lead Sponsor:
Graceway Pharmaceuticals, LLC
Conditions:
Actinic Keratosis
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should a...
Detailed Description
The primary objective of this study was to assess apoptosis by examining the gene expression profiles of actinic keratosis (AK) lesions that were treated with imiquimod 5% cream or vehicle cream once ...
Eligibility Criteria
Inclusion
- Have actinic keratoses on balding scalp
- Discontinuation of tanning bed use
- Discontinuation of moisturizers
- Avoidance of retinol products
Exclusion
- Uncontrolled, clinically significant medical condition
- Dermatologic disease other than actinic keratosis in treatment area
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2003
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00335179
Start Date
January 1 2003
End Date
July 1 2003
Last Update
July 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loma Linda University Medical Center
Loma Linda, California, United States, 92350